<code id='87DE8E7A72'></code><style id='87DE8E7A72'></style>
    • <acronym id='87DE8E7A72'></acronym>
      <center id='87DE8E7A72'><center id='87DE8E7A72'><tfoot id='87DE8E7A72'></tfoot></center><abbr id='87DE8E7A72'><dir id='87DE8E7A72'><tfoot id='87DE8E7A72'></tfoot><noframes id='87DE8E7A72'>

    • <optgroup id='87DE8E7A72'><strike id='87DE8E7A72'><sup id='87DE8E7A72'></sup></strike><code id='87DE8E7A72'></code></optgroup>
        1. <b id='87DE8E7A72'><label id='87DE8E7A72'><select id='87DE8E7A72'><dt id='87DE8E7A72'><span id='87DE8E7A72'></span></dt></select></label></b><u id='87DE8E7A72'></u>
          <i id='87DE8E7A72'><strike id='87DE8E7A72'><tt id='87DE8E7A72'><pre id='87DE8E7A72'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:knowledge    Page View:47
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In